The COVID Advisor

BY THOMAS E. LEVY, MD, JD As the acute cases of COVID have continued to decline, the prevalence of the Persistent Spike Protein (PSP) syndrome has continued to increase. The spike protein is that part of the COVID pathogen that attaches to ACE2 receptors throughout the body and permits the entry of the entire virus into the newly infected cell. There appear to be no cells, tissues, or organs in the body that are completely spared from this PSP attack once enough of it has been introduced into the body. The many mechanisms of action involved in the ultimate removal of spike protein. The persistent presence of the spike protein has been shown to be secondary to the inability to completely resolve a bout of COVID (chronic COVID or long-haul COVID) as well as the spike protein exposure from mRNA inoculation(s). And as more time has passed, the PSP syndrome following one or more mRNA shots has emerged as the most common reason for PSP, especially following a booster injection. Not surprisi...

Abstract Background: Repurposed antiparasitic drugs ivermectin and mebendazole have been evaluated as therapeutic options for COVID-19 due to their antiviral and immunomodulatory potentials. Objectives: To synthesize the most recent, high-quality evidence on the efficacy and safety of ivermectin and mebendazole for COVID-19, including extensive real-time meta-analytic and controlled trial data. Methods: Narrative review integrating the July 2025 c19ivm.org meta-analysis (>220,000 patients), recent rigorous systematic reviews, observational data, and a phase II randomized placebo-controlled trial for mebendazole. Results: Ivermectin demonstrates significant reductions in mortality and severe outcomes in large, real-time meta-analyses—especially with prophylactic and early use, though recent systematic reviews raise questions about late-stage benefit. Mebendazole exhibits biological plausibility and early evidence for improved inflammation resolution and viral clearance, as shown in a...